Olema Pharmaceuticals, INC Form 4 insider transactions

Director Ian T. Clark acquired 23,000 stock options in Olema Pharmaceuticals on June 14, 2024.

Director J. Scott Garland acquired 23,000 stock options in Olema Pharmaceuticals on June 14, 2024, according to a Form 4 filing.

Cynthia M. Butitta, a director of Olema Pharmaceuticals, acquired stock options for 23,000 shares on June 14, 2024.

Director Graham G. Walmsley reports the sale of Olema Pharmaceuticals (OLMA) common stock held indirectly through Logos Opportunities Fund I LP and Logos Opportunities Fund II LP.

Director Cyrus Harmon of Olema Pharmaceuticals sold shares of common stock on multiple dates in late May and early June under a pre-arranged 10b5-1 trading plan.

Naseem Zojwalla, Chief Medical Officer of Olema Pharmaceuticals, exercised a stock option on May 24, 2024, acquiring 9,460 shares of common stock at $4.87 per share.

Director Cyrus Harmon of Olema Pharmaceuticals sold 5,000 shares of common stock on May 6, 2024, at a weighted average price of $10.92, according to a Form 4 filing with the SEC.

Director Cyrus Harmon sold 15,000 shares of Olema Pharmaceuticals (OLMA) common stock on April 30, 2024, at a weighted average price of $9.51, according to a Form 4 filing with the SEC.

Director Cyrus Harmon of Olema Pharmaceuticals sold 20,000 shares of common stock at an average price of $10.97, according to a recent SEC filing.

Chief Medical Officer of Olema Pharmaceuticals, Naseem Zojwalla, exercised stock options on March 18, 2024, acquiring 13,700 shares of common stock.

Director Andrew Rappaport reports a pro rata distribution of Olema Pharmaceuticals common stock from SPW Investments LLC to its members.

Director Cyrus Harmon of Olema Pharmaceuticals sold shares of common stock on February 29, 2024, under a pre-arranged 10b5-1 trading plan.